48,830
edits
Difference between revisions of "P63"
Jump to navigation
Jump to search
→Negative
| Line 39: | Line 39: | ||
[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg|thumb|right|200px|Negative p63 staining in a poorly differentiated [[carcinoma]].]] | [[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg|thumb|right|200px|Negative p63 staining in a poorly differentiated [[carcinoma]].]] | ||
*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal | last1 = Pu | first1 = RT. | last2 = Pang | first2 = Y. | last3 = Michael | first3 = CW. | title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. | journal = Diagn Cytopathol | volume = 36 | issue = 1 | pages = 20-5 | month = Jan | year = 2008 | doi = 10.1002/dc.20747 | PMID = 18064689 }}</ref> | *[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal | last1 = Pu | first1 = RT. | last2 = Pang | first2 = Y. | last3 = Michael | first3 = CW. | title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. | journal = Diagn Cytopathol | volume = 36 | issue = 1 | pages = 20-5 | month = Jan | year = 2008 | doi = 10.1002/dc.20747 | PMID = 18064689 }}</ref> | ||
*[[Breast carcinoma]]. | |||
*[[Prostatic carcinoma]]. | |||
==Non-classic tumours== | ==Non-classic tumours== | ||